Vanda Pharmaceuticals | VNDA - Gross Profit On Sales

Stock Price
7.15
Daily Change
0.33 4.77%
Monthly
-13.71%
Yearly
48.54%
Q1 Forecast
6.91

Vanda Pharmaceuticals reported $50.6M in Gross Profit on Sales for its fiscal quarter ending in December of 2024.





Gross Profit On Sales Change Date
Acadia Pharmaceuticals USD 257.76M 778K Dec/2025
Agios Pharmaceuticals USD 18.09M 6.89M Dec/2025
Akebia Therapeutics USD 47.28M 1.7M Dec/2025
Alnylam Pharmaceuticals USD 829.31M 219.56M Dec/2025
Anika Therapeutics USD 19.18M 3.6M Dec/2025
Arrowhead Research USD 256.47M 228.7M Sep/2025
AstraZeneca USD 12.39B 5M Dec/2025
Bristol-Myers Squibb USD 8.79B 110M Sep/2025
Eli Lilly USD 14.59B 1.48B Sep/2025
Enanta Pharmaceuticals -22.29M 23.75M Dec/2024
Esperion Therapeutics USD 140.59M 94.57M Dec/2025
Halozyme Therapeutics USD 281.77M 2.41M Sep/2025
Heron Therapeutics USD 29.47M 3.17M Dec/2025
Insmed USD 217.69M 106.25M Dec/2025
J&J USD 16.6B 118M Dec/2025
Lexicon Pharmaceuticals USD 5.29M 8.88M Dec/2025
Ligand Pharmaceuticals USD 155.28M 82.42M Sep/2025
Merck USD 13.42B 431M Sep/2025
Minerva Neurosciences -4.27M 26.79M Dec/2024
Moderna USD 226M 583M Dec/2025
Novartis USD 10.82B 694M Sep/2025
Pfizer USD 3.54B 7.61B Sep/2025
PTC Therapeutics USD 148.38M 39.31M Dec/2025
Puma Biotechnology USD 20.32M 24.85M Sep/2024
Sangamo BioSciences -2.39M 1.09M Jun/2024
Sanofi EUR 8.45B 1.31B Dec/2025
Takeda JPY 790.55B 262.97B Dec/2025
Teva Pharmaceutical Industries USD 2.66B 351M Dec/2025
Ultragenyx Pharmaceutical USD 178M 46.06M Dec/2025
Vanda Pharmaceuticals USD 50.6M 5.5M Dec/2024
Veracyte USD 101.97M 10.69M Dec/2025